# Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

> **NCT03025308** · PHASE3 · COMPLETED · sponsor: **Alfasigma S.p.A.** · enrollment: 2731 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Placebo to match filgotinib

## Key facts

- **NCT ID:** NCT03025308
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-28
- **Primary completion:** 2025-05-16
- **Final completion:** 2025-05-16
- **Target enrollment:** 2731 (ACTUAL)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025308, "Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03025308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*